- Home
- MRVI vs CRVS Comparison
MRVI vs CRVS Comparison
Compare MRVI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRVI
- CRVS
- Stock Information
- Founded
- MRVI 2014
- CRVS 2014
- Country
- MRVI United States
- CRVS United States
- Employees
- MRVI 560
- CRVS N/A
- Industry
- MRVI Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- MRVI Health Care
- CRVS Health Care
- Exchange
- MRVI Nasdaq
- CRVS Nasdaq
- Market Cap
- MRVI 350.1M
- CRVS 305.4M
- IPO Year
- MRVI 2020
- CRVS 2016
- Fundamental
- Price
- MRVI $2.42
- CRVS $5.75
- Analyst Decision
- MRVI Hold
- CRVS Strong Buy
- Analyst Count
- MRVI 10
- CRVS 4
- Target Price
- MRVI $5.84
- CRVS $15.00
- AVG Volume (30 Days)
- MRVI 1.5M
- CRVS 518.7K
- Earning Date
- MRVI 08-11-2025
- CRVS 08-07-2025
- Dividend Yield
- MRVI N/A
- CRVS N/A
- EPS Growth
- MRVI N/A
- CRVS N/A
- EPS
- MRVI N/A
- CRVS N/A
- Revenue
- MRVI $219,830,000.00
- CRVS N/A
- Revenue This Year
- MRVI N/A
- CRVS N/A
- Revenue Next Year
- MRVI $7.23
- CRVS N/A
- P/E Ratio
- MRVI N/A
- CRVS N/A
- Revenue Growth
- MRVI N/A
- CRVS N/A
- 52 Week Low
- MRVI $1.67
- CRVS $2.54
- 52 Week High
- MRVI $9.60
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- MRVI 49.60
- CRVS 65.10
- Support Level
- MRVI $2.28
- CRVS $5.28
- Resistance Level
- MRVI $2.47
- CRVS $5.64
- Average True Range (ATR)
- MRVI 0.14
- CRVS 0.30
- MACD
- MRVI -0.01
- CRVS 0.03
- Stochastic Oscillator
- MRVI 27.45
- CRVS 77.70
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).